Perspectum Ltd’s Post

Dear Colleagues, A recent publication in the American Journal of Case Reports sheds light on an intriguing case of intrahepatic cholangiocarcinoma in a patient with Wilson's disease. This rare autosomal recessive disorder, characterized by copper accumulation, presents a range of clinical manifestations. With only 14 reported cases, the link between Wilson's disease and hepatobiliary malignancies remains unclear. The successful treatment of the patient through resection and adjuvant chemotherapy highlights the importance of careful monitoring and tailored treatment strategies for favorable outcomes. This case report prompts further exploration into the potential occurrence of intrahepatic cholangiocarcinoma in Wilson's disease. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dntvdm8Q

Dear Colleagues, A recent publication in the American Journal of Case Reports sheds light on an intriguing case of intrahepatic cholangiocarcinoma in a patient with Wilson's disease. This rare autosomal recessive disorder, characterized by copper accumulation, presents a range of clinical manifestations. With only 14 reported cases, the link between Wilson's disease and hepatobiliary malignancies remains unclear. The successful treatment of the patient through resection and adjuvant chemotherapy highlights the importance of careful monitoring and tailored treatment strategies for favorable outcomes. This case report prompts further exploration into the potential occurrence of intrahepatic cholangiocarcinoma in Wilson's disease. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/dmxC3KUd

Non-alcoholic fatty liver disease (NAFLD) impacts millions, often going undetected until advanced stages. At ArrowDx, we're pioneering the ArrowTest, a game-changing diagnostic tool for early NAFLD detection. Our innovation aims to save lives and reduce healthcare costs significantly. Stay ahead in healthcare with ArrowDx's groundbreaking solutions. Learn more about our progress and the impact of NAFLD: https://lnkd.in/gqf5WKa2 #ArrowDx #NAFLD #HealthcareInnovation

ANA-Ifa remains the preferred technique for autoimmune disease diagnostics due to its unparalleled sensitivity in detecting diverse ANA patterns, crucial for early disease detection. Despite challenges in standardization and interpretation, its ability to provide nuanced insights into complex autoimmune conditions outweighs its limitations. ANA-Ifa's reliability in identifying potential autoimmune disorders informs targeted treatment strategies, enhancing patient outcomes. As research progresses, refinements in methodology and interpretation protocols promise to further enhance its diagnostic accuracy and clinical utility, cementing its status as a cornerstone in autoimmune disease diagnostics.

“When things start to go wrong for patients with liver disease, it can go wrong very, very quickly.” The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, highlights in this video, there’s reason to be optimistic if we can carry momentum from recent hepatology breakthroughs further into MASH treatment. With the expertise of leaders Dr. Kowdley, Nadege Gunn, MD, CPI, J. Scott Overcash, M.D., and Lauri Befus, Velocity’s MASH Council to Accelerate Research Excellence (CARE) will deliver world-class operational, recruitment, and trial conduct oversight to all Velocity sites conducting MASH trials. #MASH #MASLD #Hepatology #CARECouncil

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials https://lnkd.in/dGMgqgMm

A new illustration for The Lancet Haematology's May issue. Treating Vaso-Occlusive Events in Patients with Sickle Cell Disease. The full series of illustrations for the year so far can be found at: https://lnkd.in/eD7Ggt-j #illustration #sciencecommunication #illustrator #haematology #scienceart #thelancet #scienceillustration

✨Editor’s Choice Articles Welcome to this paper on patients with cystic fibrosis and advanced lung disease, by Vincenzo Carnovale et al. from the University of Naples Federico II. 👉 Read the full article: https://lnkd.in/dMEtx7-B #clinical #medicine #openaccess #editorschoice #cysticfibrosis

Our goal is to make therapies accessible for the >90% of people with a #raredisease who lack them. Join us on October 1st for the 1st Annual Respiratory Rare Disease Accelerator Day at The Francis Crick Institute. 👉 https://lnkd.in/ezN7RDuz Globally, more than 300 million people are living with #rarediseases, of which one in 20 are related to #respiratory conditions. While rare on their own, collectively they represent significant social and economic costs. Given more than 90% of rare diseases lack an FDA-approved treatment, rare respiratory diseases represent a phenomenal growth opportunity. With our new LifeArc Centre for Rare Respiratory Diseases, we embody this bold ambition to improve diagnosis and care for patients living with rare respiratory disease and foster innovation for much-needed treatments and cures. Leading with three disease exemplars, we aim to de-risk translation from discovery through to clinical trials. We showcase primary ciliary dyskinesia (PCD), which affects 1:7000 births, which impairs mucociliary clearance leading to decline in lung function similar to #cysticfibrosis (CF). Unlike #CF, no approved treatments exist for PCD, despite a similar market size and unmet significant need. Together, we aim to change this.   This event will have wider applicability across rare disease and #personalisedmedicine showing how we can connect all the dots to market. With support from Weatherden, LifeArc, AXON and Pinsent Masons #Raredisease #CysticFibrosys #PCDResearch #genetherapy #respiratorymedicine #translationalmedicine #CRISPR #genomics #MolecularDiagnosis #bronchiectastis

Trends in 3D models of inflammatory bowel disease, now online at BBA Molecular Basis of Disease @ELSpharma. The ability to faithfully recapitulate key aspects of intestinal inflammation for achieving personalized therapies. GENEGUT #i3SPapers   https://lnkd.in/dGZmGddi